Large population studies have consistently shown that albuminuria and proteinuria indicate chronic kidney disease (CKD), and strongly and independently predict the risks of CKD progression, cardiovascular disease and all-cause mortality in both diabetic and non-diabetic individuals. Combining albuminuria measurement with eGFR provides synergistic, complementary risk-stratification for both cardiovascular disease and CKD. However, results from recent surveys of pathology laboratories indicated a lack of standardisation in primary care regarding the choice of urine protein test, units of reporting, and age and sex reference ranges. In response, the Australasian Proteinuria Consensus Working Group met throughout 2009 to 2011 to develop recommendations on the measurement of urinary albumin and protein. Seven evidence-based recommendations emanated from this meeting (Box 1).

Discussion of recommendations

1 Preferred method of testing for albuminuria in the detection of CKD

Albuminuria measurement for CKD detection is already recommended for individuals with diabetes mellitus because the bulk of published evidence linking screening or treatments with clinical outcomes has centred on albuminuria. In individuals who do not have diabetes, it is not yet established whether testing for albuminuria or proteinuria is superior for detection of CKD or for determining risk of progression. However, a retrospective longitudinal cohort study showed that urinary albumin-to-creatinine ratio (UACR) performed as well as urinary protein-to-creatinine ratio (UPCR) and 24-hour urinary albumin and protein measurements in predicting doubling of serum creatinine, commencement of renal replacement therapy and all-cause mortality.

The working group recommended initial laboratory testing for albuminuria rather than proteinuria as the preferred strategy for all individuals at risk of CKD on the basis that the former accurately predicts kidney and cardiovascular risks in population studies and renoprotective benefit in intervention trials; exhibits greater sensitivity for detecting low-grade, but clinically important albuminuria; provides improved analytical precision at low, yet diagnostically important, concentrations; allows assay standardisation; has been established to be cost-effective compared with protein or albumin reagent strips; is favoured by a number of international best-practice guidelines; and provides a simplified initial testing strategy for CKD.

Although dipstick testing of urine with protein or albumin reagent strips has long been established in clinical practice and has often been recommended for detection of CKD in patients who do not have diabetes, its usefulness as an early detection strategy is significantly limited by poor sensitivity, marked operator dependency and limited evidence of its cost-effectiveness in high-risk populations. While timed urine collection is considered the gold standard for evaluating albuminuria or proteinuria, it has logistical difficulties. Measurement of albuminuria in a first morning void specimen provides acceptable accuracy and reliability in most circumstances. Random urine specimens are acceptable if first-void specimens are impractical. Investigations have also shown that correction of urinary albumin measurements for urinary creatinine excretion accounts for variation in urinary concentration, and results in better correlation with timed urine results.

2 Target population for initial testing for CKD using UACR

Diabetes mellitus, hypertension, obesity, current smoking, established cardiovascular disease, family history of CKD and Aboriginal and Torres Strait Islander origin are risk factors for CKD. The Kidney Check Australia Taskforce and the Royal Australian College of General Practitioners (RACGP) “red book” recommend that patients with one or more of these risk factors should undergo assessment of UACR and eGFR every 1 to 2 years (annually for individuals with diabetes or hypertension).
3 Standard cut-points for microalbuminuria and macroalbuminuria based on UACR measurement

The mean cut-off for conversion of UACR to albumin excretion rate (AER) at the threshold for microalbuminuria (20 µg/min or 30 mg/day) is greater in women (UACR, 2.8–4.2 mg/mmol) than in men (UACR, 1.8–3.0 mg/mmol). Similar results have been found when using UACR thresholds to predict proteinuria of 0.5 and 1 g/day. As a result, international practice guidelines support adjustment of UACR categories by sex. The definitions and cut-points in Box 2 align with the National Health and Medical Research Council (NHMRC) guidelines for diagnosis, prevention and management of CKD in type 2 diabetes.

There is insufficient evidence to recommend ethnicity-specific or age-specific cut-points for UACR.

4 Number of UACR measurements required to establish the presence of persistent albuminuria

The high intra-individual coefficient of variation of albuminuria (30%–50%) requires that several measurements are undertaken to allow accurate categorisation of albuminuria status. If a UACR is abnormal on at least two occasions over at least 3 months, CKD is present. If the first positive UACR is a random spot, then repeat tests should be first morning void specimens. If an initial UACR test is negative, then repeated testing is not required until the next recommended testing interval.

5 Estimating urinary protein excretion from urinary albumin excretion or vice versa

In the Australian Diabetes, Obesity and Lifestyle (AusDiab) study, the proportion of protein accounted for by albumin was shown to progressively increase as total proteinuria increased. A retrospective, observational cohort study showed that the relationship between UACR and UPCR is non-linear and that 24-hour urinary protein excretion rate (AER) at the threshold for microalbuminuria (20 µg/min or 30 mg/day) is greater in women (UACR, 2.8–4.2 mg/mmol) than in men (UACR, 1.8–3.0 mg/mmol).

Similar results have been found when using UACR thresholds to predict proteinuria of 0.5 and 1 g/day. As a result, international practice guidelines support adjustment of UACR categories by sex. The definitions and cut-points in Box 2 align with the National Health and Medical Research Council (NHMRC) guidelines for diagnosis, prevention and management of CKD in type 2 diabetes.

There is insufficient evidence to recommend ethnicity-specific or age-specific cut-points for UACR.

7 Role of pathology laboratories

Laboratories should recommend a first morning void specimen for ACR as the preferred test for identification of kidney damage in all settings, although random specimens should be accepted if first morning void specimens are impractical. UACR should be reported in mg/mmol to one decimal place, and the sex-specific ratio ranges (Box 2) should be used as reference intervals. Laboratories should ensure the assays for urine albumin and creatinine are suited for purpose such that assay imprecision, bias and analytic specificity will not adversely affect clinical decision making. Laboratories should develop standardised reporting so that doctors receive the same medical information irrespective of the laboratory used.

Conclusion

Optimal detection and risk stratification in CKD requires consideration of both urinary albumin and eGFR (see recommendations of Australasian Creatinine Consensus Working Group, page 222). Standardisation of ACR as the preferred test for albuminuria in the initial assessment of all patients with possible CKD is an important step towards bringing clinical evidence to routine patient care. The testing process requires vital input from clinicians, pathologists, laboratory scientists and researchers, and the involvement of all groups is required to maximise the opportunities for improving kidney and cardiovascular health in Australia.

Competing interests: David Johnson has received consulting fees or honoraria from Amgen, Roche, Shire, Genzyme, Boehringer-Ingelheim, Baxter Healthcare and Fresenius Medical Care; support for travel to meetings from Baxter, Amgen, Roche and Shire; and payment for development of educational presentations from the Australian College of Rural and Remote Medicine and the Northern Territory Division of General Practice.

Graham Jones has received research support from Roche Diagnostics and support for travel to meetings from Roche Diagnostics and Bio-Rad.

Stephen Chadban has received research support, travel assistance, consulting fees or honoraria from Amgen, Roche, Novartis, Genzyme, Wyeth and Bristol Myers Squibb.

Richard MacIsaac has received speaker’s fees or travel support to attend meetings from Boehringer-Ingelheim, AstraZeneca, Eli Lilly, MSD, Novartis, Novo Nordisk and Sanofi Aventis. He has received grants from Novo Nordisk.

Provenance: Not commissioned; externally peer reviewed.